NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) NDMM
NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hem. Malignancies (TTI-622-01)
NCT03290950: Phase 2 - A Study of Daratumumab in Patients With NDMM wKRd-D - Manhattan Trial
NCT03158688: Phase 3 - Carfilzomib, Daratumumab and Dexa for relapsed Multiple Myeloma. (CANDOR)
NCT03031730: Phase 1: Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy RRMM Myeloma
NCT03289299 : Phase 2 - Agg. Smoldering Curative Approach Eval. Novel Therapies & Transplant ASCENT
NCT03104842: Phase 2 - GMMG - CONCEPT - Eval. iNduction, Consol. & Maint. Isatuximab Carf Len. & Dex
NCT03275285: Phase 3 - Isatuximab, Carf & Dex VS Carf And Dex In Relapse Multiple Myeloma (IKEMA)
NCT03336073: Phase 2: GEM-KyCyDex - Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma
NCT03224507: Phase 2 - Monoclonal Antibody-Based Sequential Therapy for Deep Remission in MM -MASTER
NCT02659293: Phase 3 - ATLAS Trial: Carfilzomib, Lenalidomide & Dex Vs Lenalidomide Alone After ASCT
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM
NCT02891811: Phase 2: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction
NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Len and Dex NDMM
NCT02332850: Phase Ib Study of SAR650984 With Carfilzomib for Treatment of Relapsed Multiple Myeloma
NCT02415413: Phase 2 - Carfilzomib in Patients Under 65 With High Risk Smoldering MM GEM-CESAR trial
Ph 2: Carfilzomib & lenalidomide-based treatment for newly diagnosed primary plasma cell leukemia
NCT02412878: Phase 3 - Once-weekly vs Twice-weekly Carfilzomib With Dexa in Relapsed MM (ARROW)
NCT02199665: Phase 1: Selinexor, Carfilzomib, & Dexamethasone in Treating Patients With RRMM (SINE)